Related Experiment Video
Updated: May 16, 2026
Culture and Imaging of Ex Vivo Organotypic Pseudomyxoma Peritonei Tumor Slices from Resected Human Tumor Specimens
Published on: December 9, 2022
Pseudomyxoma peritonei treated with cytoreductive surgery and hyperthermic chemotherapy: a 7-year single-center
Salvatore Virzì1, Domenico Iusco, Serena Bonomi
1Department of Surgery, Ospedale di Bentivoglio, Bentivoglio (Bologna), Italy
Aims And Background:
Pseudomyxoma peritonei (PMP) is a rare clinical entity characterized by diffuse intraabdominal gelatinous collections with mucinous implants on the peritoneal surfaces and omentum. This condition should be considered a borderline malignancy with disease progression over time. Encouraging treatment results have been recently reported with the combination of cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC).
Methods:
. From December 2003 to December 2010, 18 patients with PMP were referred to our institution. All patients underwent peritonectomy and CRS combined with HIPEC in accordance with Sugarbaker's procedure.
Results:
The mean Peritoneal Cancer Index score was 27.6 (range, 5-39). Twelve (67%) patients had disseminated peritoneal adenomucinosis and 6 (33%) peritoneal mucinous carcinomatosis. Optimal cytoreduction with no visible residual disease or residual disease ≤2.5 mm in diameter was achieved in all patients. The mean duration of the surgical procedure including HIPEC was 9 hours and 30 minutes (range, 5-13 hours); major morbidity occurred in 30% of patients and the mortality was 11%. The mean follow-up was 27 months (range, 1-72) and the 5-year overall survival 66%.
Conclusions:
In line with the existing literature, our experience suggests that patients with PMP could benefit from CRS + HIPEC in terms of survival and locoregional disease control.
Insights
Pseudomyxoma peritonei (PMP) is a rare borderline malignancy. Cytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) offers improved survival and locoregional control for PMP patients.
Area of Science:
- Oncology
- Surgical Oncology
- Gastroenterology
Background:
- Pseudomyxoma peritonei (PMP) is a rare borderline malignancy.
- Characterized by diffuse intra-abdominal gelatinous collections and peritoneal implants.
- Disease progression over time necessitates effective treatment strategies.
Purpose of the Study:
- To evaluate the efficacy of cytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) for PMP.
- To assess survival rates and locoregional disease control in PMP patients treated with CRS + HIPEC.
Main Methods:
- Retrospective analysis of 18 PMP patients treated from December 2003 to December 2010.
- All patients underwent peritonectomy and CRS with HIPEC (Sugarbaker's procedure).
- Evaluation of Peritoneal Cancer Index, cytoreduction completeness, morbidity, mortality, and survival outcomes.
Main Results:
- Optimal cytoreduction was achieved in all patients.
- Mean Peritoneal Cancer Index was 27.6.
- The 5-year overall survival rate was 66%, with 11% mortality and 30% major morbidity.
Conclusions:
- CRS + HIPEC is a beneficial treatment for PMP.
- This approach improves survival and locoregional disease control for PMP patients.
- Findings align with existing literature on PMP management.
